



NDA 22411 / S-007

SUPPLEMENT APPROVAL

Angelini Labopharm LLC
Attention: Maham Ansari, MS, RAC
Senior Associate, Regulatory Affairs
131 Morristown Road
Basking Ridge, NJ 07920

Dear Mr. Ansari:

Please refer to your Supplemental New Drug Application (sNDA) dated April 4, 2012, received April 5, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Oleptro (trazodone hydrochloride) extended-release 150 mg and 300 mg tablets.

We acknowledge receipt of your amendments dated August 1, 2012 and September 18, 2012.

This "Prior Approval" supplemental new drug application provides for class labeling revisions to the **Contraindications, Warnings, Dosage And Administration, & Medication Guide** regarding serotonin toxicity associated with the co-administration of linezolid and methylene blue as requested in an Agency supplement request letter dated March 5, 2012.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed upon labeling text and with the minor editorial revisions agreed upon in an email communication dated November 9, 2012, between you and Steve Hardeman, of this Agency.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email CDR Renmeet Grewal, Pharm.D., Senior Regulatory Project Manager, at Renmeet.Grewal@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
11/13/2012